Ontunisertib clinical trials
Also written AGMB-129.
How each study uses ontunisertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ontunisertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Who runs them
Industry 7 · Other 0
Agomab Spain S.L.U. (4) · Agomab Spain S.L. (2) · Origo Biopharma (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ontunisertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's DiseaseRecruitingPhase 2Agomab Spain S.L.U.NCT07683325Written as Ontunisertib
- Human Mass Balance Study of [14C] Ontunisertib in Healthy VolunteersRecruitingPhase 1Agomab Spain S.L.U.NCT07672574Written as Ontunisertib
- STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseCompletedPhase 2Agomab Spain S.L.U.NCT05843578Written as AGMB-129
- A Multiple Ascending Dose Study With AGMB-129 in Healthy ParticipantsCompletedPhase 1Agomab Spain S.L.U.NCT07118878Written as AGMB-129
- Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy ParticipantsCompletedPhase 1Agomab Spain S.L.NCT05937386Written as AGMB-129
- Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy ParticipantsCompletedPhase 1Agomab Spain S.L.NCT06397508Written as AGMB-129
- First in Human Study of ORG-129 in Healthy VolunteersCompletedPhase 1Origo BiopharmaNCT04933565Written as ORG-129
Codes
What other systems call ontunisertib · ClinicalTrials.gg INT017908
- UNII (FDA) SF6HGC94LKONTUNISERTIBConfirmed FDA, Wikidata
- Wikidata Q140529273ontunisertibConfirmed FDA, Wikidata
- NCI Thesaurus C215247OntunisertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SF6HGC94LK | ONTUNISERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529273 | ontunisertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C215247 | Ontunisertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.